InnoCan Pharma (TSE:INNO) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Innocan Pharma has reported positive outcomes from a long-term compassionate therapy study where dogs with osteoarthritis experienced significant pain relief and mobility improvement after receiving liposomal-CBD (LPT-CBD) injections. The therapy could offer a non-opioid alternative for chronic pain management in animals, and potentially humans, with sustained effects lasting several weeks per dose.
For further insights into TSE:INNO stock, check out TipRanks’ Stock Analysis page.
